These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 24320790)

  • 1. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
    Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
    Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
    van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
    Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.
    Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
    Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacokinetics of 2'-
    Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J
    Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pluronic-PEI copolymers enhance exon-skipping of 2'-O-methyl phosphorothioate oligonucleotide in cell culture and dystrophic mdx mice.
    Wang M; Wu B; Lu P; Tucker JD; Milazi S; Shah SN; Lu QL
    Gene Ther; 2014 Jan; 21(1):52-9. PubMed ID: 24131982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.
    Falzarano MS; Passarelli C; Ferlini A
    Nucleic Acid Ther; 2014 Feb; 24(1):87-100. PubMed ID: 24506782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD
    Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
    Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
    Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.